Analysts predict that Tyme Technologies Inc (NASDAQ:TYME) will report earnings per share of ($0.08) for the current quarter, Zacks reports. Zero analysts have made estimates for Tyme Technologies’ earnings. Tyme Technologies posted earnings of ($0.06) per share in the same quarter last year, which would suggest a negative year over year growth rate of 33.3%. The business is expected to issue its next quarterly earnings results on Wednesday, February 6th.
On average, analysts expect that Tyme Technologies will report full year earnings of ($0.30) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.37) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Tyme Technologies.
A number of research firms recently commented on TYME. BidaskClub upgraded shares of Tyme Technologies from a “strong sell” rating to a “sell” rating in a research note on Wednesday, November 28th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Tyme Technologies in a research note on Wednesday, November 7th. Finally, Zacks Investment Research cut shares of Tyme Technologies from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $7.58.
TYME stock traded up $0.21 during trading on Monday, reaching $4.13. The company had a trading volume of 2,533,100 shares, compared to its average volume of 322,131. The stock has a market capitalization of $403.79 million, a PE ratio of -19.67 and a beta of 0.75. Tyme Technologies has a twelve month low of $1.93 and a twelve month high of $8.30.
Tyme Technologies Company Profile
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.